| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 152 | 2024 | 2499 | 21.390 |
Why?
|
| Cardiology | 51 | 2024 | 574 | 7.940 |
Why?
|
| American Heart Association | 50 | 2024 | 349 | 5.410 |
Why?
|
| Stroke Volume | 32 | 2024 | 578 | 3.370 |
Why?
|
| Women's Health | 5 | 2021 | 203 | 2.730 |
Why?
|
| Advisory Committees | 20 | 2022 | 209 | 2.390 |
Why?
|
| Cardiovascular Diseases | 28 | 2024 | 2303 | 2.100 |
Why?
|
| Angiotensin Receptor Antagonists | 8 | 2023 | 151 | 2.030 |
Why?
|
| Ventricular Dysfunction, Left | 10 | 2023 | 414 | 1.950 |
Why?
|
| Cardiomyopathies | 13 | 2023 | 560 | 1.920 |
Why?
|
| Myocarditis | 5 | 2023 | 194 | 1.760 |
Why?
|
| Hospitalization | 20 | 2024 | 2202 | 1.550 |
Why?
|
| Humans | 252 | 2024 | 271636 | 1.520 |
Why?
|
| Pregnancy Complications, Cardiovascular | 5 | 2018 | 113 | 1.500 |
Why?
|
| Myocardial Infarction | 11 | 2023 | 1304 | 1.400 |
Why?
|
| United States | 79 | 2024 | 16036 | 1.320 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 8 | 2022 | 262 | 1.310 |
Why?
|
| Biomarkers | 27 | 2023 | 5111 | 1.220 |
Why?
|
| Consensus | 16 | 2024 | 1115 | 1.210 |
Why?
|
| Ventricular Remodeling | 9 | 2020 | 192 | 1.210 |
Why?
|
| Aminobutyrates | 4 | 2022 | 15 | 1.150 |
Why?
|
| Ventricular Function, Left | 15 | 2023 | 580 | 1.080 |
Why?
|
| Natriuretic Peptide, Brain | 10 | 2023 | 340 | 1.070 |
Why?
|
| Research Report | 9 | 2022 | 144 | 1.070 |
Why?
|
| Stroke | 3 | 2023 | 1093 | 1.060 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2023 | 771 | 1.030 |
Why?
|
| Practice Guidelines as Topic | 22 | 2024 | 2429 | 1.030 |
Why?
|
| Heart Diseases | 7 | 2023 | 739 | 1.010 |
Why?
|
| Troponin I | 2 | 2018 | 131 | 0.970 |
Why?
|
| Cardiomyopathy, Dilated | 3 | 2020 | 225 | 0.960 |
Why?
|
| Coronavirus Infections | 7 | 2020 | 633 | 0.950 |
Why?
|
| Cardiac Rehabilitation | 2 | 2021 | 23 | 0.940 |
Why?
|
| Pneumonia, Viral | 6 | 2020 | 709 | 0.910 |
Why?
|
| Obesity | 8 | 2024 | 2952 | 0.890 |
Why?
|
| Disease Management | 17 | 2024 | 1111 | 0.880 |
Why?
|
| Concept Formation | 1 | 2023 | 28 | 0.870 |
Why?
|
| Peripheral Arterial Disease | 3 | 2023 | 267 | 0.870 |
Why?
|
| Cardiovascular System | 5 | 2022 | 151 | 0.820 |
Why?
|
| Databases, Factual | 6 | 2020 | 2287 | 0.810 |
Why?
|
| Valsartan | 4 | 2023 | 32 | 0.800 |
Why?
|
| Evidence-Based Medicine | 11 | 2019 | 1059 | 0.770 |
Why?
|
| Betacoronavirus | 4 | 2020 | 522 | 0.760 |
Why?
|
| Periodicals as Topic | 5 | 2023 | 323 | 0.760 |
Why?
|
| Metabolic Syndrome | 4 | 2022 | 374 | 0.750 |
Why?
|
| Clinical Trials as Topic | 15 | 2024 | 3852 | 0.730 |
Why?
|
| Prognosis | 31 | 2023 | 22525 | 0.700 |
Why?
|
| Autoantigens | 1 | 2021 | 248 | 0.700 |
Why?
|
| Spike Glycoprotein, Coronavirus | 2 | 2021 | 212 | 0.700 |
Why?
|
| Blood Pressure | 8 | 2021 | 1595 | 0.690 |
Why?
|
| Adrenergic beta-Antagonists | 7 | 2023 | 330 | 0.690 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 4 | 2023 | 33 | 0.690 |
Why?
|
| Health Status Disparities | 3 | 2019 | 309 | 0.680 |
Why?
|
| Healthcare Disparities | 4 | 2020 | 645 | 0.670 |
Why?
|
| Risk Factors | 35 | 2024 | 18016 | 0.660 |
Why?
|
| Digoxin | 2 | 2010 | 55 | 0.660 |
Why?
|
| Cardiovascular Agents | 5 | 2024 | 117 | 0.660 |
Why?
|
| Pulmonary Wedge Pressure | 3 | 2016 | 64 | 0.650 |
Why?
|
| Societies, Medical | 10 | 2024 | 1349 | 0.650 |
Why?
|
| Comorbidity | 13 | 2022 | 2435 | 0.640 |
Why?
|
| Treatment Outcome | 39 | 2024 | 33846 | 0.620 |
Why?
|
| Peripartum Period | 5 | 2021 | 34 | 0.600 |
Why?
|
| Sex Factors | 11 | 2021 | 2202 | 0.600 |
Why?
|
| Tetrazoles | 4 | 2022 | 102 | 0.590 |
Why?
|
| Atherosclerosis | 7 | 2023 | 957 | 0.580 |
Why?
|
| Electrocardiography | 4 | 2013 | 1194 | 0.580 |
Why?
|
| Pandemics | 7 | 2022 | 1603 | 0.580 |
Why?
|
| Heart Transplantation | 8 | 2021 | 904 | 0.570 |
Why?
|
| Heart-Assist Devices | 3 | 2023 | 1053 | 0.570 |
Why?
|
| Risk Assessment | 16 | 2023 | 6876 | 0.570 |
Why?
|
| Puerperal Disorders | 4 | 2017 | 51 | 0.570 |
Why?
|
| Atrial Pressure | 1 | 2016 | 7 | 0.550 |
Why?
|
| Dyspnea | 2 | 2014 | 421 | 0.550 |
Why?
|
| Female | 74 | 2023 | 148992 | 0.540 |
Why?
|
| Acute Disease | 9 | 2023 | 2510 | 0.530 |
Why?
|
| Hyperlipidemias | 2 | 2016 | 237 | 0.530 |
Why?
|
| Acute Kidney Injury | 2 | 2022 | 780 | 0.500 |
Why?
|
| Inpatients | 1 | 2020 | 695 | 0.500 |
Why?
|
| Hospital Mortality | 9 | 2023 | 1315 | 0.500 |
Why?
|
| Cocaine | 1 | 2017 | 245 | 0.500 |
Why?
|
| Telemedicine | 1 | 2022 | 546 | 0.500 |
Why?
|
| Drug Combinations | 3 | 2022 | 634 | 0.490 |
Why?
|
| Health Promotion | 1 | 2019 | 510 | 0.480 |
Why?
|
| Cardiotonic Agents | 2 | 2023 | 163 | 0.480 |
Why?
|
| Cardiac Resynchronization Therapy | 2 | 2011 | 30 | 0.470 |
Why?
|
| Incidence | 11 | 2023 | 5856 | 0.470 |
Why?
|
| Cocaine-Related Disorders | 1 | 2017 | 240 | 0.470 |
Why?
|
| Coronary Artery Bypass | 5 | 2021 | 568 | 0.470 |
Why?
|
| Mortality | 4 | 2024 | 353 | 0.470 |
Why?
|
| Chagas Cardiomyopathy | 1 | 2014 | 47 | 0.470 |
Why?
|
| Tumor Necrosis Factor-alpha | 9 | 2010 | 1613 | 0.470 |
Why?
|
| Diabetes Mellitus | 4 | 2018 | 1072 | 0.470 |
Why?
|
| Exercise Test | 4 | 2024 | 315 | 0.460 |
Why?
|
| Lung Diseases | 2 | 2014 | 755 | 0.460 |
Why?
|
| Male | 68 | 2023 | 128836 | 0.450 |
Why?
|
| Global Health | 1 | 2019 | 691 | 0.450 |
Why?
|
| Hypertension | 4 | 2021 | 1617 | 0.440 |
Why?
|
| Diuretics | 4 | 2023 | 181 | 0.420 |
Why?
|
| Neurotransmitter Agents | 3 | 2012 | 174 | 0.420 |
Why?
|
| Quality of Life | 7 | 2022 | 4745 | 0.410 |
Why?
|
| Ventricular Pressure | 2 | 2011 | 44 | 0.410 |
Why?
|
| Hypotension | 2 | 2012 | 237 | 0.410 |
Why?
|
| Nervous System Diseases | 3 | 2021 | 522 | 0.410 |
Why?
|
| Propanolamines | 1 | 2011 | 49 | 0.400 |
Why?
|
| Myocardial Contraction | 2 | 2011 | 306 | 0.400 |
Why?
|
| Cytokines | 11 | 2021 | 2837 | 0.390 |
Why?
|
| Wolff-Parkinson-White Syndrome | 1 | 2012 | 76 | 0.390 |
Why?
|
| Severity of Illness Index | 12 | 2024 | 4391 | 0.390 |
Why?
|
| Vasodilator Agents | 3 | 2014 | 238 | 0.390 |
Why?
|
| Carbazoles | 1 | 2011 | 92 | 0.390 |
Why?
|
| Heart Valve Prosthesis Implantation | 4 | 2023 | 487 | 0.380 |
Why?
|
| Percutaneous Coronary Intervention | 4 | 2020 | 369 | 0.380 |
Why?
|
| Chest Pain | 1 | 2012 | 172 | 0.380 |
Why?
|
| Renin-Angiotensin System | 3 | 2020 | 112 | 0.370 |
Why?
|
| Troponin T | 4 | 2016 | 263 | 0.370 |
Why?
|
| Chronic Disease | 7 | 2022 | 1849 | 0.370 |
Why?
|
| Biphenyl Compounds | 3 | 2022 | 192 | 0.370 |
Why?
|
| Primary Prevention | 4 | 2021 | 243 | 0.370 |
Why?
|
| ST Elevation Myocardial Infarction | 3 | 2020 | 142 | 0.370 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2024 | 1435 | 0.370 |
Why?
|
| Middle Aged | 49 | 2023 | 90349 | 0.360 |
Why?
|
| Perioperative Care | 4 | 2015 | 447 | 0.360 |
Why?
|
| Aged | 43 | 2023 | 73421 | 0.360 |
Why?
|
| Acute Coronary Syndrome | 4 | 2018 | 256 | 0.350 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2010 | 103 | 0.350 |
Why?
|
| Endpoint Determination | 3 | 2015 | 183 | 0.350 |
Why?
|
| Sodium | 3 | 2023 | 353 | 0.350 |
Why?
|
| Quality Indicators, Health Care | 3 | 2024 | 364 | 0.350 |
Why?
|
| Writing | 2 | 2021 | 104 | 0.340 |
Why?
|
| Cardiac Catheterization | 4 | 2016 | 693 | 0.340 |
Why?
|
| Patient Readmission | 4 | 2023 | 592 | 0.340 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2009 | 27 | 0.340 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2009 | 75 | 0.330 |
Why?
|
| Prosthesis Implantation | 1 | 2011 | 244 | 0.330 |
Why?
|
| Risk Reduction Behavior | 2 | 2021 | 223 | 0.320 |
Why?
|
| Heart Defects, Congenital | 6 | 2019 | 1781 | 0.310 |
Why?
|
| Peptide Fragments | 5 | 2023 | 1327 | 0.310 |
Why?
|
| Shock, Cardiogenic | 3 | 2023 | 239 | 0.310 |
Why?
|
| Spironolactone | 2 | 2011 | 26 | 0.310 |
Why?
|
| Prostatic Hyperplasia | 1 | 2009 | 222 | 0.310 |
Why?
|
| Heart Failure, Systolic | 1 | 2008 | 34 | 0.310 |
Why?
|
| Time Factors | 15 | 2023 | 13116 | 0.300 |
Why?
|
| Coronary Artery Disease | 5 | 2021 | 946 | 0.300 |
Why?
|
| Diabetes Complications | 1 | 2009 | 316 | 0.290 |
Why?
|
| Sleep Apnea, Obstructive | 3 | 2021 | 248 | 0.290 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2018 | 2672 | 0.290 |
Why?
|
| Disease Progression | 9 | 2023 | 6905 | 0.290 |
Why?
|
| Hemodynamics | 8 | 2023 | 973 | 0.280 |
Why?
|
| Artificial Intelligence | 4 | 2024 | 430 | 0.280 |
Why?
|
| Health Services Needs and Demand | 2 | 2021 | 250 | 0.280 |
Why?
|
| Japan | 3 | 2021 | 237 | 0.270 |
Why?
|
| Thrombolytic Therapy | 2 | 2020 | 258 | 0.270 |
Why?
|
| Inflammation | 2 | 2020 | 2532 | 0.270 |
Why?
|
| Glomerular Filtration Rate | 3 | 2022 | 603 | 0.270 |
Why?
|
| Severe Acute Respiratory Syndrome | 3 | 2020 | 85 | 0.260 |
Why?
|
| Goals | 3 | 2019 | 190 | 0.260 |
Why?
|
| Metabolic Diseases | 2 | 2024 | 140 | 0.260 |
Why?
|
| Receptors, Tumor Necrosis Factor | 4 | 2008 | 214 | 0.250 |
Why?
|
| Cause of Death | 3 | 2017 | 786 | 0.240 |
Why?
|
| Prevalence | 8 | 2023 | 3423 | 0.240 |
Why?
|
| Precision Medicine | 1 | 2013 | 1206 | 0.240 |
Why?
|
| Follow-Up Studies | 14 | 2017 | 15254 | 0.240 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2018 | 352 | 0.240 |
Why?
|
| Immunoglobulins, Intravenous | 3 | 2020 | 187 | 0.240 |
Why?
|
| Kidney | 2 | 2018 | 2265 | 0.240 |
Why?
|
| Echocardiography | 4 | 2023 | 1240 | 0.230 |
Why?
|
| Immunoglobulin G | 3 | 2008 | 1139 | 0.230 |
Why?
|
| Asymptomatic Diseases | 1 | 2024 | 104 | 0.230 |
Why?
|
| Ultrasonography | 3 | 2012 | 1935 | 0.220 |
Why?
|
| Registries | 5 | 2019 | 2246 | 0.220 |
Why?
|
| Transitional Care | 1 | 2023 | 22 | 0.220 |
Why?
|
| Peptidyl-Dipeptidase A | 2 | 2020 | 84 | 0.220 |
Why?
|
| Heart Valve Prosthesis | 4 | 2013 | 327 | 0.220 |
Why?
|
| Heart Valve Diseases | 2 | 2015 | 197 | 0.220 |
Why?
|
| Research Design | 5 | 2020 | 1580 | 0.210 |
Why?
|
| Personal Protective Equipment | 2 | 2020 | 63 | 0.210 |
Why?
|
| Aortic Valve | 4 | 2015 | 484 | 0.210 |
Why?
|
| Sleep Apnea, Central | 1 | 2022 | 9 | 0.210 |
Why?
|
| Technology | 1 | 2023 | 103 | 0.210 |
Why?
|
| Adult | 25 | 2024 | 81791 | 0.210 |
Why?
|
| Confidence Intervals | 5 | 2010 | 758 | 0.210 |
Why?
|
| China | 2 | 2021 | 645 | 0.210 |
Why?
|
| Anterior Wall Myocardial Infarction | 1 | 2022 | 13 | 0.200 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2022 | 64 | 0.200 |
Why?
|
| Body Mass Index | 5 | 2018 | 2254 | 0.200 |
Why?
|
| Antihypertensive Agents | 2 | 2023 | 434 | 0.200 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2004 | 309 | 0.200 |
Why?
|
| Heart Function Tests | 3 | 2014 | 76 | 0.200 |
Why?
|
| Complementary Therapies | 1 | 2022 | 118 | 0.190 |
Why?
|
| Myocardium | 6 | 2021 | 1251 | 0.190 |
Why?
|
| Patient Selection | 5 | 2020 | 2043 | 0.190 |
Why?
|
| Retrospective Studies | 19 | 2022 | 39731 | 0.190 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2023 | 238 | 0.190 |
Why?
|
| Healthy Lifestyle | 1 | 2021 | 42 | 0.190 |
Why?
|
| Protein Precursors | 2 | 2021 | 252 | 0.190 |
Why?
|
| Hypoglycemic Agents | 4 | 2022 | 620 | 0.190 |
Why?
|
| Molecular Mimicry | 1 | 2021 | 70 | 0.190 |
Why?
|
| Electric Stimulation Therapy | 1 | 2022 | 132 | 0.190 |
Why?
|
| Monitoring, Physiologic | 2 | 2022 | 535 | 0.190 |
Why?
|
| New Zealand | 1 | 2021 | 70 | 0.190 |
Why?
|
| Patient Care Team | 4 | 2015 | 829 | 0.190 |
Why?
|
| Public Opinion | 1 | 2021 | 77 | 0.190 |
Why?
|
| Aortic Valve Stenosis | 4 | 2014 | 401 | 0.190 |
Why?
|
| Sexism | 1 | 2021 | 54 | 0.190 |
Why?
|
| Educational Status | 1 | 2022 | 393 | 0.190 |
Why?
|
| Patient-Centered Care | 1 | 2024 | 321 | 0.180 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2022 | 147 | 0.180 |
Why?
|
| Atrial Fibrillation | 2 | 2022 | 750 | 0.180 |
Why?
|
| Australia | 1 | 2021 | 261 | 0.180 |
Why?
|
| Specialization | 1 | 2021 | 129 | 0.180 |
Why?
|
| India | 1 | 2021 | 313 | 0.180 |
Why?
|
| Pain Management | 3 | 2015 | 715 | 0.180 |
Why?
|
| Telemetry | 1 | 2020 | 41 | 0.180 |
Why?
|
| Shock, Septic | 1 | 2022 | 186 | 0.180 |
Why?
|
| Survival Analysis | 7 | 2014 | 9323 | 0.170 |
Why?
|
| Pregnancy | 6 | 2018 | 8089 | 0.170 |
Why?
|
| Physicians, Women | 1 | 2021 | 99 | 0.170 |
Why?
|
| Canada | 1 | 2021 | 442 | 0.170 |
Why?
|
| Occupational Health | 1 | 2020 | 93 | 0.170 |
Why?
|
| Neprilysin | 1 | 2019 | 64 | 0.170 |
Why?
|
| Enkephalins | 1 | 2019 | 35 | 0.170 |
Why?
|
| Proportional Hazards Models | 6 | 2014 | 5113 | 0.170 |
Why?
|
| Texas | 8 | 2017 | 6434 | 0.170 |
Why?
|
| Ventricular Function, Right | 2 | 2018 | 113 | 0.170 |
Why?
|
| Ethics Committees, Research | 1 | 2019 | 41 | 0.160 |
Why?
|
| Health Status | 2 | 2020 | 633 | 0.160 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 101 | 0.160 |
Why?
|
| Thalidomide | 1 | 2002 | 595 | 0.160 |
Why?
|
| Heart | 3 | 2022 | 1214 | 0.160 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2020 | 169 | 0.160 |
Why?
|
| Nurse Practitioners | 2 | 2019 | 61 | 0.160 |
Why?
|
| Cohort Studies | 10 | 2016 | 9467 | 0.160 |
Why?
|
| Leadership | 1 | 2021 | 261 | 0.160 |
Why?
|
| Research Support as Topic | 1 | 2019 | 120 | 0.160 |
Why?
|
| Obesity, Morbid | 2 | 2017 | 238 | 0.160 |
Why?
|
| Hyponatremia | 2 | 2014 | 87 | 0.160 |
Why?
|
| Standard of Care | 1 | 2020 | 275 | 0.150 |
Why?
|
| Triage | 1 | 2020 | 257 | 0.150 |
Why?
|
| Wearable Electronic Devices | 1 | 2020 | 115 | 0.150 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2018 | 59 | 0.150 |
Why?
|
| Cardiac Output, Low | 1 | 1998 | 77 | 0.150 |
Why?
|
| Longitudinal Studies | 1 | 2023 | 2051 | 0.150 |
Why?
|
| C-Reactive Protein | 2 | 2012 | 567 | 0.150 |
Why?
|
| Research Personnel | 1 | 2019 | 154 | 0.150 |
Why?
|
| Prospective Studies | 10 | 2022 | 13385 | 0.150 |
Why?
|
| Quality of Health Care | 4 | 2015 | 630 | 0.150 |
Why?
|
| Social Media | 1 | 2021 | 211 | 0.140 |
Why?
|
| Myocardial Ischemia | 2 | 2014 | 436 | 0.140 |
Why?
|
| Endovascular Procedures | 2 | 2013 | 469 | 0.140 |
Why?
|
| Population Surveillance | 1 | 2021 | 650 | 0.140 |
Why?
|
| Glucose | 1 | 2023 | 1242 | 0.140 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2022 | 441 | 0.140 |
Why?
|
| Virus Diseases | 1 | 2020 | 392 | 0.140 |
Why?
|
| Patient Discharge | 5 | 2022 | 708 | 0.140 |
Why?
|
| Machine Learning | 1 | 2020 | 358 | 0.140 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2020 | 1163 | 0.140 |
Why?
|
| Hepatomegaly | 1 | 2016 | 72 | 0.140 |
Why?
|
| Continuous Positive Airway Pressure | 2 | 2015 | 80 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 533 | 0.140 |
Why?
|
| Relaxin | 1 | 2016 | 22 | 0.130 |
Why?
|
| Terminology as Topic | 3 | 2015 | 420 | 0.130 |
Why?
|
| Behavior Therapy | 1 | 2018 | 304 | 0.130 |
Why?
|
| History, 21st Century | 2 | 2020 | 422 | 0.130 |
Why?
|
| Immunosuppressive Agents | 1 | 2002 | 1444 | 0.130 |
Why?
|
| Prolactin | 1 | 2016 | 174 | 0.130 |
Why?
|
| Inflammation Mediators | 2 | 2017 | 408 | 0.130 |
Why?
|
| Enzyme Inhibitors | 1 | 2023 | 1965 | 0.130 |
Why?
|
| Maximum Tolerated Dose | 1 | 2019 | 1323 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2016 | 122 | 0.130 |
Why?
|
| Ascites | 1 | 2016 | 216 | 0.130 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2021 | 1232 | 0.130 |
Why?
|
| Critical Care | 1 | 2021 | 810 | 0.120 |
Why?
|
| Procollagen | 1 | 2014 | 32 | 0.120 |
Why?
|
| Cross-Sectional Studies | 4 | 2022 | 4502 | 0.120 |
Why?
|
| Lower Extremity | 1 | 2017 | 284 | 0.120 |
Why?
|
| Exercise | 2 | 2021 | 1214 | 0.120 |
Why?
|
| Health Personnel | 1 | 2020 | 648 | 0.120 |
Why?
|
| Edema | 1 | 2016 | 263 | 0.120 |
Why?
|
| Physician Assistants | 1 | 2015 | 78 | 0.120 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2017 | 595 | 0.120 |
Why?
|
| Veterans | 3 | 2023 | 1778 | 0.120 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2015 | 107 | 0.120 |
Why?
|
| Rheumatic Fever | 1 | 2014 | 20 | 0.120 |
Why?
|
| Secondary Prevention | 4 | 2018 | 322 | 0.120 |
Why?
|
| Fibrinolytic Agents | 1 | 2016 | 303 | 0.120 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 312 | 0.110 |
Why?
|
| Observational Studies as Topic | 1 | 2014 | 148 | 0.110 |
Why?
|
| Case-Control Studies | 5 | 2021 | 6230 | 0.110 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2014 | 188 | 0.110 |
Why?
|
| Hypercholesterolemia | 2 | 2013 | 269 | 0.110 |
Why?
|
| Patient Care Management | 1 | 2014 | 94 | 0.110 |
Why?
|
| Hospitals, Veterans | 2 | 2013 | 380 | 0.110 |
Why?
|
| Monocytes | 1 | 2017 | 788 | 0.110 |
Why?
|
| Collagen Type I | 1 | 2014 | 191 | 0.110 |
Why?
|
| Survival Rate | 6 | 2017 | 12530 | 0.110 |
Why?
|
| beta-Thalassemia | 1 | 2013 | 33 | 0.110 |
Why?
|
| Foundations | 1 | 2013 | 23 | 0.110 |
Why?
|
| Hypertension, Pulmonary | 2 | 2018 | 471 | 0.110 |
Why?
|
| Life Style | 2 | 2013 | 622 | 0.110 |
Why?
|
| Guideline Adherence | 4 | 2018 | 647 | 0.110 |
Why?
|
| Coronary Angiography | 1 | 2016 | 568 | 0.110 |
Why?
|
| Myocardial Revascularization | 1 | 2014 | 135 | 0.110 |
Why?
|
| Sex Characteristics | 2 | 2021 | 434 | 0.110 |
Why?
|
| Weight Reduction Programs | 1 | 2013 | 74 | 0.110 |
Why?
|
| Hypoxia | 1 | 2015 | 468 | 0.100 |
Why?
|
| Interleukin-6 | 3 | 2020 | 1066 | 0.100 |
Why?
|
| Phenotype | 3 | 2021 | 6510 | 0.100 |
Why?
|
| Coronary Disease | 1 | 2016 | 783 | 0.100 |
Why?
|
| Blood Urea Nitrogen | 1 | 2012 | 100 | 0.100 |
Why?
|
| Editorial Policies | 2 | 2023 | 77 | 0.100 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2014 | 850 | 0.100 |
Why?
|
| Multivariate Analysis | 3 | 2009 | 4352 | 0.100 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2012 | 27 | 0.100 |
Why?
|
| Killer Cells, Natural | 1 | 2017 | 959 | 0.100 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2019 | 636 | 0.100 |
Why?
|
| Nanomedicine | 1 | 2012 | 53 | 0.100 |
Why?
|
| Biomedical Research | 1 | 2019 | 801 | 0.100 |
Why?
|
| Diffusion of Innovation | 1 | 2013 | 153 | 0.100 |
Why?
|
| Vocabulary | 1 | 2011 | 27 | 0.100 |
Why?
|
| Receptors, Cytokine | 3 | 2001 | 183 | 0.100 |
Why?
|
| Endocardium | 2 | 2021 | 56 | 0.100 |
Why?
|
| Models, Cardiovascular | 2 | 2011 | 189 | 0.100 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2023 | 252 | 0.100 |
Why?
|
| Statistics as Topic | 1 | 2012 | 458 | 0.090 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2012 | 229 | 0.090 |
Why?
|
| Physicians | 2 | 2019 | 870 | 0.090 |
Why?
|
| Central Venous Pressure | 1 | 2011 | 27 | 0.090 |
Why?
|
| Program Development | 1 | 2012 | 264 | 0.090 |
Why?
|
| General Surgery | 1 | 2014 | 330 | 0.090 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2011 | 121 | 0.090 |
Why?
|
| Anticholesteremic Agents | 1 | 2013 | 256 | 0.090 |
Why?
|
| Predictive Value of Tests | 5 | 2020 | 4998 | 0.090 |
Why?
|
| Outpatients | 1 | 2014 | 469 | 0.090 |
Why?
|
| Systole | 1 | 2011 | 222 | 0.090 |
Why?
|
| Blood Sedimentation | 1 | 2010 | 38 | 0.090 |
Why?
|
| Europe | 2 | 2024 | 659 | 0.090 |
Why?
|
| Viral Tropism | 2 | 2020 | 41 | 0.090 |
Why?
|
| Overweight | 1 | 2013 | 487 | 0.090 |
Why?
|
| Preventive Health Services | 1 | 2010 | 73 | 0.090 |
Why?
|
| Forecasting | 1 | 2013 | 705 | 0.090 |
Why?
|
| Hospital Costs | 2 | 2022 | 251 | 0.090 |
Why?
|
| Cholesterol, HDL | 1 | 2011 | 371 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 1322 | 0.080 |
Why?
|
| Diagnostic Imaging | 2 | 2014 | 1177 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2016 | 1588 | 0.080 |
Why?
|
| Aged, 80 and over | 9 | 2020 | 31032 | 0.080 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 1 | 2009 | 40 | 0.080 |
Why?
|
| Sexual Behavior | 1 | 2012 | 321 | 0.080 |
Why?
|
| Chemokines | 1 | 2010 | 294 | 0.080 |
Why?
|
| Point-of-Care Systems | 1 | 2012 | 215 | 0.080 |
Why?
|
| Biopsy | 3 | 2021 | 3544 | 0.080 |
Why?
|
| Internal Mammary-Coronary Artery Anastomosis | 1 | 2008 | 14 | 0.080 |
Why?
|
| Young Adult | 6 | 2020 | 22094 | 0.080 |
Why?
|
| Haemophilus Infections | 1 | 2009 | 110 | 0.080 |
Why?
|
| Haemophilus influenzae | 1 | 2009 | 161 | 0.080 |
Why?
|
| Peptides | 1 | 2014 | 1528 | 0.080 |
Why?
|
| Etanercept | 3 | 2008 | 69 | 0.080 |
Why?
|
| Medical Records | 1 | 2009 | 447 | 0.080 |
Why?
|
| Coronary Vessels | 1 | 2012 | 643 | 0.080 |
Why?
|
| Cholesterol | 1 | 2011 | 681 | 0.080 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2023 | 506 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2012 | 2334 | 0.080 |
Why?
|
| Cholesterol, LDL | 1 | 2011 | 583 | 0.080 |
Why?
|
| Clinical Competence | 2 | 2013 | 1325 | 0.070 |
Why?
|
| Heart Rate | 3 | 2006 | 760 | 0.070 |
Why?
|
| Cultural Diversity | 1 | 2008 | 80 | 0.070 |
Why?
|
| Odds Ratio | 2 | 2009 | 2335 | 0.070 |
Why?
|
| Pneumonia, Bacterial | 1 | 2009 | 135 | 0.070 |
Why?
|
| Age Factors | 4 | 2020 | 5509 | 0.070 |
Why?
|
| Early Diagnosis | 2 | 2023 | 316 | 0.070 |
Why?
|
| Cluster Analysis | 1 | 2010 | 1074 | 0.070 |
Why?
|
| Seasons | 1 | 2008 | 337 | 0.070 |
Why?
|
| Streptococcus pneumoniae | 1 | 2009 | 404 | 0.070 |
Why?
|
| Recurrence | 2 | 2012 | 4884 | 0.070 |
Why?
|
| Metformin | 1 | 2010 | 395 | 0.070 |
Why?
|
| Thiazolidinediones | 1 | 2007 | 153 | 0.070 |
Why?
|
| Anemia | 2 | 2021 | 730 | 0.070 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2006 | 116 | 0.070 |
Why?
|
| Cardiac Output | 2 | 2020 | 197 | 0.060 |
Why?
|
| Common Data Elements | 2 | 2015 | 6 | 0.060 |
Why?
|
| Matrix Metalloproteinases | 2 | 2002 | 139 | 0.060 |
Why?
|
| Double-Blind Method | 4 | 2011 | 2619 | 0.060 |
Why?
|
| Animals | 12 | 2021 | 62757 | 0.060 |
Why?
|
| Attitude of Health Personnel | 1 | 2011 | 917 | 0.060 |
Why?
|
| Length of Stay | 3 | 2021 | 2010 | 0.060 |
Why?
|
| Heart Arrest | 2 | 2020 | 376 | 0.060 |
Why?
|
| Health Services Research | 2 | 2011 | 243 | 0.060 |
Why?
|
| Fellowships and Scholarships | 1 | 2009 | 408 | 0.060 |
Why?
|
| Staphylococcus aureus | 1 | 2009 | 563 | 0.060 |
Why?
|
| Reproducibility of Results | 4 | 2020 | 6208 | 0.060 |
Why?
|
| Heart Ventricles | 2 | 2020 | 846 | 0.060 |
Why?
|
| Information Technology | 1 | 2024 | 11 | 0.060 |
Why?
|
| Adolescent | 5 | 2019 | 32609 | 0.060 |
Why?
|
| Quality Improvement | 2 | 2024 | 916 | 0.060 |
Why?
|
| Heart Atria | 1 | 2006 | 357 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2014 | 6266 | 0.060 |
Why?
|
| Evidence-Based Practice | 2 | 2015 | 129 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2009 | 1188 | 0.050 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2023 | 115 | 0.050 |
Why?
|
| Electronic Health Records | 1 | 2011 | 969 | 0.050 |
Why?
|
| Staphylococcal Infections | 1 | 2009 | 682 | 0.050 |
Why?
|
| Antiviral Agents | 2 | 2020 | 1254 | 0.050 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2002 | 37 | 0.050 |
Why?
|
| Equipment Design | 2 | 2020 | 1206 | 0.050 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2012 | 677 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 4890 | 0.050 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2022 | 14 | 0.050 |
Why?
|
| Bacteremia | 1 | 2009 | 722 | 0.050 |
Why?
|
| Biliopancreatic Diversion | 1 | 2002 | 5 | 0.050 |
Why?
|
| Blood Coagulation Disorders | 1 | 2004 | 115 | 0.050 |
Why?
|
| Return to Sport | 1 | 2022 | 4 | 0.050 |
Why?
|
| Drug Evaluation | 1 | 2002 | 435 | 0.050 |
Why?
|
| Policy | 1 | 2022 | 53 | 0.050 |
Why?
|
| Norepinephrine | 1 | 2003 | 285 | 0.050 |
Why?
|
| Respiratory Function Tests | 1 | 2003 | 355 | 0.050 |
Why?
|
| Calcium Channel Blockers | 1 | 2022 | 145 | 0.050 |
Why?
|
| Hyperkalemia | 1 | 2003 | 80 | 0.050 |
Why?
|
| Patient Safety | 2 | 2020 | 655 | 0.050 |
Why?
|
| Ambulatory Care Facilities | 1 | 2024 | 302 | 0.050 |
Why?
|
| Public Health Surveillance | 1 | 2021 | 64 | 0.050 |
Why?
|
| Surgical Procedures, Operative | 2 | 2015 | 357 | 0.050 |
Why?
|
| Endothelin Receptor Antagonists | 1 | 2001 | 26 | 0.050 |
Why?
|
| Academic Medical Centers | 2 | 2019 | 690 | 0.050 |
Why?
|
| Echovirus Infections | 1 | 2020 | 2 | 0.050 |
Why?
|
| Coxsackievirus Infections | 1 | 2020 | 11 | 0.050 |
Why?
|
| Erythema Infectiosum | 1 | 2020 | 10 | 0.050 |
Why?
|
| Data Mining | 1 | 2021 | 86 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2007 | 5102 | 0.050 |
Why?
|
| Hospitals, Rural | 1 | 2020 | 8 | 0.050 |
Why?
|
| Anti-HIV Agents | 1 | 2004 | 352 | 0.050 |
Why?
|
| Hospital Bed Capacity | 1 | 2020 | 29 | 0.050 |
Why?
|
| Nursing Homes | 1 | 2021 | 102 | 0.050 |
Why?
|
| Roseolovirus Infections | 1 | 2020 | 39 | 0.040 |
Why?
|
| Total Quality Management | 1 | 2000 | 39 | 0.040 |
Why?
|
| Cloud Computing | 1 | 2020 | 15 | 0.040 |
Why?
|
| Blood Pressure Determination | 1 | 2020 | 109 | 0.040 |
Why?
|
| Hospitals, Urban | 1 | 2020 | 98 | 0.040 |
Why?
|
| Patient Participation | 1 | 2024 | 449 | 0.040 |
Why?
|
| Education, Medical, Continuing | 2 | 2012 | 234 | 0.040 |
Why?
|
| Smartphone | 1 | 2020 | 45 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2002 | 593 | 0.040 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 58 | 0.040 |
Why?
|
| Th17 Cells | 1 | 2021 | 163 | 0.040 |
Why?
|
| Hospitals, Teaching | 1 | 2020 | 128 | 0.040 |
Why?
|
| HIV Infections | 2 | 2020 | 2156 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2021 | 274 | 0.040 |
Why?
|
| Receptors, Virus | 1 | 2020 | 153 | 0.040 |
Why?
|
| Motor Activity | 2 | 2013 | 718 | 0.040 |
Why?
|
| Contracts | 1 | 2019 | 9 | 0.040 |
Why?
|
| Perioperative Period | 1 | 2020 | 150 | 0.040 |
Why?
|
| Risk | 1 | 2004 | 1950 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2020 | 191 | 0.040 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2022 | 347 | 0.040 |
Why?
|
| Quality Assurance, Health Care | 2 | 2015 | 612 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2021 | 274 | 0.040 |
Why?
|
| Postoperative Hemorrhage | 1 | 2020 | 138 | 0.040 |
Why?
|
| Drug Approval | 1 | 2020 | 176 | 0.040 |
Why?
|
| Serine Endopeptidases | 1 | 2020 | 280 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2020 | 270 | 0.040 |
Why?
|
| Research | 1 | 2021 | 431 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 544 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2020 | 754 | 0.040 |
Why?
|
| Nurses | 1 | 2019 | 85 | 0.040 |
Why?
|
| Leukocytes | 1 | 2020 | 426 | 0.040 |
Why?
|
| Infusion Pumps, Implantable | 1 | 1998 | 65 | 0.040 |
Why?
|
| Liver Diseases | 1 | 2003 | 605 | 0.040 |
Why?
|
| Communication | 1 | 2024 | 854 | 0.040 |
Why?
|
| Dimerization | 1 | 1998 | 318 | 0.040 |
Why?
|
| Kidney Diseases | 1 | 2003 | 731 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2020 | 549 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2022 | 1285 | 0.040 |
Why?
|
| Ambulatory Care | 2 | 2015 | 604 | 0.040 |
Why?
|
| Reference Values | 2 | 2011 | 1154 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2001 | 544 | 0.040 |
Why?
|
| Continuity of Patient Care | 1 | 2019 | 223 | 0.040 |
Why?
|
| Mass Screening | 2 | 2021 | 1547 | 0.040 |
Why?
|
| Myocytes, Cardiac | 1 | 2002 | 709 | 0.040 |
Why?
|
| Weight Loss | 1 | 2021 | 638 | 0.040 |
Why?
|
| Informed Consent | 1 | 2020 | 413 | 0.040 |
Why?
|
| Blood Transfusion | 1 | 2020 | 582 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2008 | 10259 | 0.030 |
Why?
|
| Leptin | 1 | 2018 | 312 | 0.030 |
Why?
|
| Tachycardia, Ventricular | 1 | 2019 | 206 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2020 | 668 | 0.030 |
Why?
|
| Cytomegalovirus Infections | 1 | 2020 | 485 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2018 | 296 | 0.030 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2020 | 475 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 7463 | 0.030 |
Why?
|
| Surgical Wound Dehiscence | 1 | 1996 | 125 | 0.030 |
Why?
|
| Drug-Eluting Stents | 1 | 2016 | 86 | 0.030 |
Why?
|
| Turkey | 1 | 2015 | 66 | 0.030 |
Why?
|
| Classification | 1 | 2015 | 40 | 0.030 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2015 | 22 | 0.030 |
Why?
|
| Drug Prescriptions | 1 | 2018 | 321 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2017 | 442 | 0.030 |
Why?
|
| Aspirin | 1 | 2018 | 392 | 0.030 |
Why?
|
| Hepatitis C | 1 | 2020 | 551 | 0.030 |
Why?
|
| Echocardiography, Transesophageal | 1 | 1996 | 291 | 0.030 |
Why?
|
| Confidentiality | 1 | 2015 | 126 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2018 | 559 | 0.030 |
Why?
|
| Pharyngitis | 1 | 2014 | 47 | 0.030 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2014 | 64 | 0.030 |
Why?
|
| Mitral Valve Stenosis | 1 | 2014 | 51 | 0.030 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2015 | 108 | 0.030 |
Why?
|
| Anthropometry | 1 | 2014 | 264 | 0.030 |
Why?
|
| Pyridines | 1 | 2001 | 1311 | 0.030 |
Why?
|
| Aortic Diseases | 1 | 2015 | 195 | 0.030 |
Why?
|
| Postoperative Complications | 2 | 2021 | 5688 | 0.030 |
Why?
|
| Influenza, Human | 1 | 2020 | 762 | 0.030 |
Why?
|
| Iron Chelating Agents | 1 | 2013 | 33 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2018 | 746 | 0.030 |
Why?
|
| Iron Overload | 1 | 2013 | 34 | 0.030 |
Why?
|
| Diet, Reducing | 1 | 2013 | 85 | 0.030 |
Why?
|
| Pericardial Effusion | 1 | 2014 | 125 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2014 | 502 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2019 | 5919 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1998 | 2252 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 308 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2014 | 352 | 0.030 |
Why?
|
| Algorithms | 2 | 2016 | 3922 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 2365 | 0.030 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2014 | 147 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2016 | 691 | 0.030 |
Why?
|
| Equipment Failure | 1 | 2013 | 198 | 0.030 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2012 | 47 | 0.030 |
Why?
|
| Public Policy | 1 | 2012 | 55 | 0.030 |
Why?
|
| Decision Making | 1 | 2019 | 1242 | 0.030 |
Why?
|
| Angiography | 1 | 2013 | 351 | 0.020 |
Why?
|
| Logistic Models | 2 | 2009 | 3460 | 0.020 |
Why?
|
| Patients | 1 | 2013 | 248 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 873 | 0.020 |
Why?
|
| Streptococcal Infections | 1 | 2014 | 312 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2017 | 3077 | 0.020 |
Why?
|
| Family Practice | 1 | 2011 | 132 | 0.020 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2013 | 508 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2012 | 453 | 0.020 |
Why?
|
| Pulmonary Circulation | 1 | 2011 | 132 | 0.020 |
Why?
|
| Internal Medicine | 1 | 2011 | 160 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2015 | 2105 | 0.020 |
Why?
|
| DNA Damage | 1 | 1998 | 1989 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 2398 | 0.020 |
Why?
|
| Rats | 1 | 1998 | 6633 | 0.020 |
Why?
|
| Triglycerides | 1 | 2011 | 622 | 0.020 |
Why?
|
| Efficiency | 1 | 2009 | 93 | 0.020 |
Why?
|
| Endocrinology | 1 | 2011 | 158 | 0.020 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2009 | 93 | 0.020 |
Why?
|
| Solubility | 1 | 2008 | 251 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2014 | 937 | 0.020 |
Why?
|
| Collagen | 1 | 2011 | 737 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 5195 | 0.020 |
Why?
|
| Palliative Care | 1 | 2019 | 2156 | 0.020 |
Why?
|
| Drug Administration Schedule | 2 | 2007 | 3538 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2015 | 1227 | 0.020 |
Why?
|
| Protein Stability | 1 | 2008 | 376 | 0.020 |
Why?
|
| Electrooculography | 1 | 2006 | 8 | 0.020 |
Why?
|
| Infusions, Intravenous | 2 | 2001 | 1439 | 0.020 |
Why?
|
| Community-Acquired Infections | 1 | 2009 | 286 | 0.020 |
Why?
|
| Electromyography | 1 | 2006 | 231 | 0.020 |
Why?
|
| Diet | 1 | 2013 | 1489 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 1327 | 0.020 |
Why?
|
| Polysomnography | 1 | 2006 | 170 | 0.020 |
Why?
|
| Prosthesis Failure | 1 | 2006 | 201 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2009 | 742 | 0.010 |
Why?
|
| Electroencephalography | 1 | 2006 | 968 | 0.010 |
Why?
|
| Receptor, Endothelin B | 1 | 2001 | 8 | 0.010 |
Why?
|
| Receptor, Endothelin A | 1 | 2001 | 18 | 0.010 |
Why?
|
| Endothelin-1 | 1 | 2001 | 63 | 0.010 |
Why?
|
| Vascular Resistance | 1 | 2001 | 215 | 0.010 |
Why?
|
| Coronary Circulation | 1 | 2001 | 257 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2002 | 1832 | 0.010 |
Why?
|
| Morbidity | 1 | 2000 | 404 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2012 | 8587 | 0.010 |
Why?
|
| Documentation | 1 | 2000 | 215 | 0.010 |
Why?
|
| Benchmarking | 1 | 2000 | 284 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 1999 | 477 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 7788 | 0.010 |
Why?
|
| Walking | 1 | 1999 | 274 | 0.010 |
Why?
|
| Infant | 1 | 2012 | 13887 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2012 | 16943 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1999 | 3070 | 0.010 |
Why?
|
| Child | 1 | 2012 | 30401 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1996 | 3035 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 1999 | 4193 | 0.000 |
Why?
|
| Signal Transduction | 1 | 2002 | 12219 | 0.000 |
Why?
|